Goldman Sachs recently hosted the "Healthcare CEOs Unscripted" conference, and our health care analyst Max Macaluso was particularly interested in the interview with Merck's (MRK +0.19%) CEO, Kenneth Frazier. Max discusses the three takeaways he thought were most important from the talk -- including Merck's business strategy compared to the high profile spinouts recently engineered by Abbott (ABT +0.28%) and Pfizer (PFE +0.12%) -- and also offers his 2013 outlook for Merck.
Does This Pharma Have Spinout Envy?
By Max Macaluso and Brenton Flynn – Jan 4, 2013 at 6:00PM
NYSE: MRK
Merck
Market Cap
$260B
Today's Change
(0.19%) $0.20
Current Price
$104.83
Price as of November 28, 2025 at 1:00 PM ET
While other big pharmas are spinning out businesses, Merck stays on course.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo